A first-in-human Phase 1 trial of #RE104, a short-acting #serotonergic #psychedelic prodrug, has just been published in JCP. In this placebo-controlled RCT, RE104 was safe and well-tolerated up to 30 mg, producing psychedelic effects that lasted about 3-4 hours.

🔗 journals.lww.com/psychopharma...